A 52-year-old dentist with kappa light chain multiple myeloma relapsed 6 months after 180 mg/m 2 melphalan and an autograft. A partial remission had been attained after the autograft. Relapse occurred while he was on dexamethasone maintenance therapy. Chemotherapy was not an option due to low blood counts. Thalidomide was administered at relatively high doses (escalated up to 700 mg daily and continued for 4 months). There was a prompt decline in urine protein from 6067 mg/day to 2177 mg/day within a month. The response continued to improve with achievement of near-complete remission within 6 months and a decline in urine protein to 413 mg/day. Subsequently, grade 3 neutropenia and peripheral neuropathy required dose reduction to 200 mg/day. Disease activity parameters continued to improve on the lower dose of thalidomide. Nine months after starting thalidomide, the patient is in near-complete remission, enjoys an excellent quality of life, and has returned to work. We conclude that thalidomide can effectively control myeloma relapsing after high-dose chemotherapy, and may be especially useful in resistant cases or those unable to tolerate further chemotherapy. Bone Marrow Transplantation (2000) 25, 1319-1320. Keywords: multiple myeloma; thalidomide Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment option in multiple myeloma but results are hampered by high toxicity and relapse rates.
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment option in multiple myeloma but results are hampered by high toxicity and relapse rates. 1 Despite excellent response rates, 2 most myeloma patients relapse after autologous transplantation. 3 The approach to patients relapsing after an autograft is difficult. Recent results suggest that thalidomide as a single agent is useful in patients with relapsed myeloma. plant, and who obtained an excellent response with thalidomide.
Case report
A 52-year-old male dentist was diagnosed as having stage IIIA kappa light chain multiple myeloma in February 1997. There was no response to seven courses of vincristine-melphalan-methylprednisolone and three courses of infusional cyclophosphamide-vincristine-doxorubicin-methylprednisolone. He received intermittent fractionated radiation to areas of significant bone pain with marked pain relief. Collection of an adequate number of stem cells required two attempts at mobilization: once with mitoxantrone, etoposide and G-CSF, and once with cyclophosphamide and G-CSF.
The patient received high-dose melphalan (180 mg/m 2 ) and an autograft in June 1998. Hematologic recovery was slow, but interferon-␣2b was started on day 48 when the platelets reached 80 ϫ 10 9 /l. This had to be discontinued after 3 weeks due to profound thrombocytopenia. Instead, oral dexamethasone (40 mg/day for 4 days every month) was administered as maintenance. The patient attained a partial remission after the transplant, and the urine total protein declined to 100 mg (mostly light chain) on dexamethasone maintenance.
Rapidly progressive relapse was detected 6 months post transplant with an increase from 3 g to over 6 g proteinuria (mostly light chain) over 2 months. Dexamethasone maintenance was withdrawn and oral thalidomide was commenced a month later at a dose of 200 mg/day. Chemotherapy could not be considered due to thrombocytopenia. Excellent tolerance led to cautious dose escalation to 700 mg/day, which was maintained for 4 months. During this phase, the major biochemical parameter of myeloma activity (urine protein) progressively regressed ( Figure 1) .
The development of leukopenia (neutrophils: 0.8 ϫ 10 9 /l) and peripheral neuropathy manifesting with tingling and numbness of hands and feet necessitated dose reduction to 200 mg of thalidomide. The symptoms of neuropathy as well as leukopenia reversed on 200 mg of thalidomide. At present, 9 months after thalidomide and 17 months post autograft, the patient is in near-complete remission with 300 mg protein in the urine (mostly non-specific), leads an J a n 9 9 F e b 9 9 M a r 9 9 A p r 9 9 M a y 9 9 J u n 9 9 J u l 9 9 A u g 9 9 S e p 9 9 O c t 9 9 N o v 9 9 Urine total protein (mg per 24 h) Figure 1 Urine total protein (mg per 24 h). The patient was autografted in June 1998. excellent quality of life and has started practising dentistry again.
Discussion
Singhal et al 4 reported that oral thalidomide achieved 35% responses in an unfavorable group of heavily pre-treated patients including many who had been transplanted previously. Intriguingly, thalidomide displayed negligible hematologic toxicity with a median time to response ranging from 20 to 66 days for the different subgroups of responders. In the same study only 9% of cases discontinued the drug due to adverse reactions, chiefly related to the nervous and digestive systems.
Our report is in keeping with the observation of Singhal et al. 4 Of interest, we found that in our patient thalidomide resulted in the best ever response in the entire course of his disease and treatment. While proteinuria had declined to 100 mg post autograft, this was mainly monoclonal light chain. The stable proteinuria of 300 mg on thalidomide is mostly non-specific proteinuria. It was interesting to note that there was some hematologic toxicity in our patient. It is possible that the extent of prior therapy and poor hematologic recovery could have contributed to this. The resolution of peripheral neuropathy and improvement in leukopenia on decreasing the dose of thalidomide suggests that the toxicities of the drug are reversible. Maintenance of the remission on the lower dose of thalidomide suggests that once an initial response has been achieved, a lower dose may be sufficient to maintain the response. However, more data are needed to determine the exact dose-response relationship.
The mechanism of action of thalidomide in myeloma is unclear. 4 It may be related to its anti-angiogenic properties 6 or various other immunomodulatory activities. 4 Angiogenesis inhibition is an attractive potential mechanism because bone marrow angiogenesis is prominent in myeloma and correlates with disease progression. 6 In conclusion, our experience with thalidomide suggests that thalidomide monotherapy is a reasonable option for myeloma patients with a suboptimal marrow reserve or those failing standard therapy including high-dose chemotherapy.
